EcoDrugPlus

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSSCUG00000003749
Gene Symbol: KCNJ3
3 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSSCUG00000012302
Gene Symbol: KCNJ5
3 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSSCUG00000006885
Gene Symbol: KCNK2
3 Cross references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSSCUG00000003543
Gene Symbol: KCNK9
3 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSSCUG00000008569
Gene Symbol: KCNA5
1 Cross references
169 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSSCUG00000007237
Gene Symbol: KCND3
3 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSSCUG00000002825
Gene Symbol: KCNQ2
3 Cross references
248 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSSCUG00000004929
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSSCUG00000015927
Gene Symbol: KCNQ5
3 Cross references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin 1

Ensembl ID : ENSSCUG00000007259
Gene Symbol: PSEN1
3 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin 2

Ensembl ID : ENSSCUG00000003093
Gene Symbol: PSEN2
3 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 2

Ensembl ID : ENSSCUG00000001423
Gene Symbol: PTGER2
1 Cross references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).